Relay Therapeutics, Inc.

Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM’s Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (Nasdaq: TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE: NVS) and GlaxoSmithKline (NYSE: GSK). ITM’s Supervisory Board and the company overall will benefit from Dr. Weber’s deep expertise as it advances its lead Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and continues advancing its radiopharmaceutical pipeline and medical radioisotope manufacturing business. “Dr. Weber’s impressive track record in building transformative oncology biotech companies speaks volumes for her business acumen and her dedication to improving the lives of people living with cancer. Her profound industry and scientific knowledge, including her demonstrated ability to bring novel compounds through the clinic to FDA approval, will be an invaluable asset to ITM,” said Udo J. Vetter, Chairman of the Supervisory Board of ITM. “The expansion of our Supervisory Board and its insights ensures that ITM is optimally positioned to continue accelerating the growth of its radiopharmaceutical pipeline and medical radioisotope business.” Dr. Weber is a physician-scientist with a distinguished clinical and academic career and extensive leadership expertise in global pharmaceutical development. As the President, Chief Executive Officer and Founder of Tango Therapeutics, she led the company’s transition to being publicly listed and the development of its precision oncology product candidates based on the genetic principle of synthetic lethality. As a Venture Partner at Third Rock Ventures, she led teams in creating new oncology drug discovery companies, including Tango Therapeutics, Neon Therapeutics (acquired by BioNTech (Nasdaq: BNTX)) and Relay Therapeutics (Nasdaq: RLAY). “As a physician and business executive devoted to fighting cancer, I recognize the significant potential of targeted radiopharmaceutical therapy to improve the precision oncology treatment paradigm and outcomes for patients. I look forward to working with ITM’s Supervisory Board and Leadership Team as the company plans an NDA submission for ITM-11 and expands its pipeline with various promising alpha- and beta-emitting radioisotopes coupled with novel targeting agents,” said Dr. Weber. Prior to her tenure at Third Rock Ventures, Dr. Weber was Senior Vice President, Oncology Translational Medicine at Novartis and Vice President, Oncology Discovery and Translational Medicine at GlaxoSmithKline, where she was instrumental in leading clinical studies and obtaining FDA approvals for numerous drugs including Zykadia®, Kisqali®, Vijoice® and Promacta®. Dr. Weber received her Doctor of Medicine from the University of Washington and has been affiliated with the University of Pennsylvania, Yale University and the Dana-Farber Cancer Institute. She is a member of the Board of Directors at Tango Therapeutics, Revolution Medicines Inc. (Nasdaq: RVMD), Parabilis Medicines and Sesame Therapeutics. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com Attachments 20250409_Barbara Weber, M.D., Elected to ITM Supervisory Board Barbara Weber, M.D., Elected to ITM Supervisory Board

Eli Lilly is buying Scorpion Therapeutics but will spin out its non-PI3Kα pipeline assets to create a new company. \n Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion.Novartis won FDA approval for its PI3Kα inhibitor Piqray in 2019. Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO-783 after comparing clinical data on the molecule to its next-generation candidates. At the time, Lilly’s chief scientific officer Daniel Skovronsky, M.D., Ph.D., said a next-generation prospect would enter the clinic in 2025.The Scorpion deal secures Lilly a clinical-phase candidate ahead of schedule. Scorpion published phase 1 data on its candidate STX-478 last year, generating early evidence that the molecule may have an edge over Piqray and Itovebi and hold its own against Relay Therapeutics’ rival next-generation prospect.Lilly has persuaded Scorpion to part with the candidate and the rest of its work on the PI3Kα pathway in return for up to $2.5 billion in upfront payments and milestones. The Big Pharma is buying Scorpion but will spin out its non-PI3Kα pipeline assets to create a new company. Scorpion’s staffers will join the new company, which will be owned by the biotech’s current shareholders and Lilly. STX-478 and Lilly’s internal PI3Kα candidates are designed to be more selective than Piqray and Itovebi, both of which hit both the wild-type and mutant forms of PI3Kα. Inhibition of the wild-type enzyme in healthy tissue can result in metabolic dysfunction and ultimately cause dose-limiting toxicities, leading Lilly, Scorpion and others to design molecules that selectively target the mutant PI3Kα enzyme.Lilly said last year that LOXO-783 didn’t cause hyperglycemia—an adverse event associated with Piqray and Itovebi—in the clinic but questioned whether the efficacy was good enough in the months before dropping the candidate.Scorpion reported (PDF) a 23% response rate in breast cancer patients when STX-478 was used as a single agent. All cases of hyperglycemia, diarrhea and rash—adverse events associated with inhibition of wild-type PI3Kα—were grade 1 or 2. 

Relay Therapeutics’ stock $RLAY rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα inhibitor in breast cancer. In the Phase 1/2 trial, 64 patients with second-line PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer saw a median progression-free survival of 11.4 months when taking 600 mg of RLY-2608 plus fulvestrant. There was also a 39% overall response rate. “These updated data help build on previously reported results that show a level of benefit that had not previously been seen with non-selective PI3Kα inhibitors,” Relay’s president of R&D Don Bergstrom said in a statement. For safety, most of the treatment-related adverse events were low-grade and “manageable and reversible.” Only two patients discontinued treatment. Based on the data, which were presented Wednesday at the San Antonio Breast Cancer Symposium, Relay plans to start a second-line pivotal study of RLY-2608 and chemotherapy in 2025, with the full data from the Phase 1/2 trial coming out next year. The drug is also in another arm of the study, which is still enrolling, that pairs it with fulvestrant and Novartis’ Kisqali. Another cohort will be treated with RLY-2608 plus atirmociclib, Pfizer’s experimental CDK4 inhibitor, in a trial that recently started. Relay had two rounds of job cuts this year. It laid off 10% of its staff in October , preceded by a smaller downsizing in July.